were female (Table 1) . Eight patients presented with tinnitus/bruit, five with intracranial hemorrhage, four with cavernous sinus syndrome, and one each with seizures, ataxia, visual field loss, and hiccups. Two patients had previously undergone (incomplete) treatment of their DAVFs at other institutions: one, transvenous sinus occlusion; the other, transarterial PVA particles. All patients underwent a sixvessel diagnostic angiography study before and after embolization to confirm occlusion of their DAVFs. One patient harbored three separate DAVFs. For descriptive statistical analysis, the DAVFs were classified according to the Cognard grading scale 3 and clinical outcomes were stratified based on the Glasgow Outcome Scale. 13 
Transarterial Embolization Technique
All procedures were performed in patients after induction of general endotracheal anesthesia. To access arteries for diagnostic angiography studies and embolizations we used a No. 5 or 6 French catheter appropriate for each specific case. A variety of guidewire-directed microcatheters were used, including the Prowler-10, Prowler-14, and RapidTransit (Cordis Neurovascular, Miami Lakes, FL) as well as the Excel and Renegade (Boston Scientific, Fremont, CA). Polymeric embolic agents (NBCA) used in this series included Histoacryl (Yocan, Toronto, ON, Canada) and TruFill (Cordis Neurovascular). In the final six cases we switched from Histoacryl to TruFill because of its commercial availability. The volume of NBCA in Ethiodol was approximately 30 to 35% for TruFill and 20 to 25% for Histoacryl. This difference in percent volume was due to subtle differences in polymerization characteristics between the two preparations of NBCA.
Prior to microcatheterization, several appropriate arterial conduits for flow-arrest delivery were identified based on their size, length, accessibility, tortuosity, extent and type of collateralization, and flow rate. Once a feeding artery was selected, the microcatheter was advanced distally until the catheter was wedged into position. Confirmation of the flow-arrest status as well as the location and character of the targeted fistula was achieved with the aid of a microinjection of contrast agent. The microcatheter and arterial territory distal to the microcatheter tip was then flushed with D5W. Because D5W impedes polymerization of NBCA, the wedged feeding artery situated distal to the microcatheter tip was essentially converted into a functional extension of the catheter itself. In a controlled manner, NBCA was subsequently injected across the pathological arteriovenous fistula and into the parent venous apparatus, thereby occluding the lesion (Fig. 1) .
In several high-flow DAVFs with extensive collateralization, inflow was diminished by preparatory embolization of accessory pedicles with the use of PVA particles (Cordis Neurovascular). These preparatory embolizations were performed specifically to optimize the subsequent injection of glue through the wedged catheter. Improvement in the subsequent process of glue injection was achieved by decreasing the competing inflow into the shunt domain, which, if unchecked, frequently causes fragmentation of the glue column and thus leads to premature polymerization and incomplete closure of the shunt. Furthermore, by preemptively reducing overall arteriovenous shunting, unintended systemic embolization of NBCA was prevented and conditions favoring slow, controlled delivery of glue to the targeted fistula were created. Although PVA particles are inadequate for the definitive occlusion of DAVFs, they are useful adjunctive agents for safely and acutely reducing collateral participation in the shunt supply. Polyvinyl alcohol is an embolic agent infrequently associated with ischemic cranial neuropathies, providing predictable collateral vessel penetration determined by the particle size selected (usually 45-250 m).
Results

Angiography Evaluation
The parent (recipient) venous structure of the DAVFs in our cohort included 11 leptomeningeal veins, eight transverse/sigmoid sinuses, three cavernous sinuses, and one sphenoparietal sinus. All 23 DAVFs were supplied by multiple arteries. Based on angiography analysis, a mean 4.1 potential arterial conduits (range two-nine conduits) were identified as suitable for NBCA embolization. Nineteen (83%) of the DAVFs exhibited cortical venous drainage. Seven patients (33%) had a thrombosed major dural sinus. Cognard grades were as follows: one Grade I, three Grade IIA, seven Grade IIB, four Grade III, and eight Grade IV.
Treatment and Outcome
The NBCA permeation of the shunt with occlusion of the immediate venous apparatus was observed in all DAVFs treated in this series. No residual arteriovenous shunting was demonstrated on postembolization six-vessel control angiography studies of any DAVF following adequate deposition of NBCA into the recipient venous outlet. Figures  1 to 3 illustrate representative cases. Twenty of 21 patients underwent one embolization session each, whereas one patient underwent two sessions. This latter patient had three separate DAVFs, and because of the complexity of her case, which required therapeutic catheterization of both ophthalmic arteries, the embolizations were staged in two sessions to treat all three fistulas safely.
The arterial conduits for the definitive injection of NBCA were selected from branches of 10 middle meningeal arteries, five ascending pharyngeal arteries, two occipital arteries, one posterior meningeal artery, one artery of the falx cerebelli, one artery of the foramen rotundum, one accessory meningeal artery, and two ethmoid divisions of the ophthalmic artery. In 16 DAVFs (70%), NBCA was successfully deposited across the pathological arteriovenous connection into the recipient venous structure on the initial injection attempt. The remaining seven DAVFs (30%) required more than one injection attempt to deposit NBCA through the fistulous connection: four cases required attempts through two pedicles, two required three, and one required four. Of the 11 NBCA injection attempts that did not initially result in adequate permeation of the fistula, seven were attributable to premature polymerization of NBCA proximal to the shunt and four resulted from inadequate occlusion of the recipient venous apparatus due to fragmentation of the glue stream arising from excessive collateral inflow. Three high-flow DAVFs were treated with preparatory devascularization of collateral inflow by using PVA particles before the definitive transarterial NBCA deposition. No complication occurred in this series. All 21 patients had a Glasgow Outcome Scale score of 5 when discharged from the hospital. The average clinical follow up was 18.6 months (range 2-46 months). No patient developed symptoms referable to the DAVF during the follow-up period. In 12 patients without manifestations that could be clinically monitored (for example, tinnitus or cavernous sinus syndrome), follow-up diagnostic angiograms obtained at 6 to 12 months postembolization revealed no evidence of DAVF recurrence. 
Discussion
Our patients were treated with a novel transarterial flowarrest embolization technique in which diluted NBCA was slowly injected through a wedged catheter, previously advanced via a feeding artery, across the fistula and into the parent venous structure, and thus eliminating the pathological arteriovenous connection. As initially described for the treatment of brain arteriovenous malformations, 5 with this technique the arterial pedicle beyond the tip of the wedged microcatheter becomes a functional extension of the catheter, establishing an effective embolization point closer to the fistula, thereby facilitating both delivery of the liquid embolic agent across the fistula site and permeation of the perifistulous collateral network. cludes the immediately receptive venous apparatus. Use of this embolization technique has not been previously described in the treatment of DAVFs.
In our view, in certain situations the permeation of DAVFs with a liquid polymer delivered transarterially is preferable to transvenous coil embolization for the following reasons: 1) the fistula site is definitely occluded, reducing the likelihood that shunt flow may be diverted into alternative venous pathways and predisposing it to intraparenchymal hemorrhage; 1,2,12,24 2) treatment is not limited by venous access problems, including thrombosed or stenotic dural sinuses and high-grade lesions draining directly into cortical veins; 3) cure does not necessarily require the sacrifice of functional venous pathways that may drain normal brain parenchyma; 4) specific complications of transvenous embolization may be avoided in certain circumstances (for example, catheterization of the inferior petrosal sinus, which is often performed for transvenous access to the cavernous sinus and tentorial DAVFs, may cause sixth nerve palsy or venous rupture producing subarachnoid hemorrhage); 14, 21, 24 and 5) development of de novo DAVFs in separate locations after transvenous coil embolization may occur due to venous hypertension-induced angiogenesis from coil occlusion of major dural sinuses. 18, 26 Recently, there have been multiple reports in which authors specifically describe intracranial DAVFs as being completely treated with the use of transvenous parent sinus occlusion, but later complications occurred by the development of a de novo DAVF at a separate intracranial location. [15] [16] [17] 20, 28 The radiographic and clinical outcomes in the present study compare favorably with those of other published series in which investigators used transvenous embolization or open surgical techniques (Table 2) . 4, 10, 11, 22, 24, 25, 27, 29 Although our obliteration rate was higher than those previously reported with earlier transarterial techniques, [7] [8] [9] 23 prior series generally included transarterial coil-, PVA-, and poly-mer-based methods resulting in occlusion of arteries proximal to the fistula site, permitting later reestablishment of arteriovenous shunting through adjacent collateral networks.
To maximize the efficacy of each transarterial NBCA embolization, a catheter must be securely wedged into position and a true flow-arrest state must be established. Furthermore, the injection dynamic should be predicated on the catheter's distance from the fistula, the shunting rate, the size of the feeding artery engaged, and the extent of collateralization present. Although all DAVFs in our series were obliterated with the transarterial injection of NBCA, 35% were treated using adjunctive embolizations with PVA or NBCA. All of these patients harbored high-flow shunts in which preemptive devascularization of the collateral inflow before definitive occlusion of the shunt with NBCA was performed to minimize fragmentation and premature polymerization of the definitive glue column, and to prevent uncontrolled systemic venous embolization with NBCA.
Possible complications associated with transarterial NBCA embolization of DAVFs may include ischemic cranial nerve palsies, transcollateral embolization into normal cerebral arteries, and systemic venous embolization with NBCA. Although none of these complications occurred in our series, 30% of cases required more than one attempt to cast glue across the pathological shunting point. Multiple attempts of injecting NBCA were required, particularly when the catheter's wedged position deteriorated or was not achieved within the initially selected dural branch. Successive attempts, however, are generally possible due to the multiplicity of potential target arteries available for each DAVF (mean number of feeding arteries 4.1, range twonine arteries). Moreover, although the unsuccessful NBCA depositions were not in and of themselves curative (reflecting proximal occlusion of specific branches participating in the supply of the shunt), they nevertheless served to reduce collateral inflow, making subsequent NBCA embolization attempts more likely to be successful in curing the DAVF. Although not encountered in our experience, rupture of the catheterized vessel during glue injection is possible. Injecting the polymer in a slow, controlled manner likely prevents this complication from occurring.
During the study period, 11 additional patients with DAVFs admitted to our institution were treated with transvenous coiling of the parent venous sinus. Our decision to use a transvenous approach in these select cases was determined by the specific angioarchitecture and flow characteristics of each DAVF. In our experience, a primary transve- 
